# UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

> **NCT03158883** · EARLY_PHASE1 · COMPLETED · sponsor: **Megan Daly, MD** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Avelumab
- **RADIATION:** Stereotactic ablative radiotherapy (SAR)

## Key facts

- **NCT ID:** NCT03158883
- **Lead sponsor:** Megan Daly, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-17
- **Primary completion:** 2020-04-09
- **Final completion:** 2020-06-24
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158883, "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03158883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*